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doi:10.1016/j.jfma.2012.03.002Background/Purpose: Retinopathy of prematurity (ROP) is a leading cause of childhood blind-
ness. This retrospective study investigated ROP, including incidence, demographic informa-
tion,risk factors, treatments, and refractive outcomes, in southern Taiwan over a 10-year
period.
Methods: The authors retrieved the National Cheng Kung University Hospital database
between the years 2000 and 2009 for newborns with a gestational age less than 32 weeks
and/or with a birth weight less than 1500 g who had been screened for ROP. We recorded
sex, birth weight, gestational age, in-hospital versus out-of-hospital birth, paternal and
maternal ages, whether there were multiple gestations, parity, Apgar scores, length of
hospital stay, risk factors, presence and severity of ROP and whether it was treated, and
refraction at the last visit. Regression analyses were performed to identify risk factors for ROP.
Results: A total of 503 live births were included. ROP was identified in 190 (37.8%) and met
criteria for treatment in 59 (11.7%).ROP was diagnosed as stage 1, 2, 3, 4, and 5 in 61
(12.1%), 36 (7.2%), 81 (16.1%), 11 (2.2%), and 1 (0.2%) infant, respectively. Lower birth weightof Ophthalmology, National Cheng Kung University College of Medicine and Hospital, 138 Sheng-Li
m (S.-H. Tseng).
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446 M.-L. Li et al.and younger gestational age were risk factors for greater severity of ROP (p < 0.001). Of the
167 with extremely low birth weight (<1000 g), 118 (70.7%) had ROP and 49 (29.3%) required
treatment.On univariate analysis, low birth weight, younger gestational age, and risk factors-
such as respiratory distress syndrome, chronic lung disease, patent ductus arteriosus, surfac-
tant usage, indomethacin usage, sepsis, upper gastrointestinal bleeding, blood transfusion,
and necrotizing enterocolitis were associated with ROP. Multivariate logistic regression anal-
ysis showed that only lower birth weight was a significant and independent risk factor for
ROP. Myopia (76%)and anisometropia (28%)were common in advanced ROP.
Conclusion: Low birth weight is a major risk factor for ROP. Infants with extremely low birth
weight had a higher risk of severe ROP. Common ocular sequelae of advanced ROP were myopia
and anisometropia.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Premature infants are at risk of retinopathy of prematurity
(ROP), characterized by abnormal vascular development of
the retina.1 ROP may progress rapidly to an advanced stage
in which malformation of eye structures leads to blindness
as a result of retinal detachment, macular folds, and
refractive or strabismic amblyopia.1e4
The International Classification of Retinopathy of
Prematurity (ICROP) allows for comparison of the incidences
and outcomes of this disease across populations.1,5 Previous
large-scale studies such as the Cryotherapy for Retinopathy
of Prematurity (CRYO-ROP)2,5,6 and Early Treatment of
Retinopathy of Prematurity (ETROP)7 studies showed that
early intervention is effective in preventing loss of visual
acuity and adverse anatomic outcomes. Despite increased
awareness of and improved treatments for ROP, however,
this disease remains a leading cause of childhood blindness,
accounting for up to 10% of cases in developed countries.8
A number of ROP studies have been conducted in Taiwan,
reporting on the incidence,9e15 characteristics,9e11,13e17
treatment options,14,18 and visual outcomes of ROP. 14,19
Over the past decade, medical care for neonates in Taiwan
has advanced greatly, as evidenced by the increased survival
rate of low-birth-weight (BW) infants, including those with
very low birth weight (VLBW) (<1500 g) and those with
extremely lowbirthweight (ELBW) (<1000 g).9,20,21 As a result
of these increased survival rates, ophthalmologists are to
examine more infants for evaluation of ROP. We conducted
the study to investigate the incidence, severity, treatment
and treatment outcomes, and the risk factors for ROP among
lowBW infants at a tertiarymedical center in southern Taiwan
for the 10-year period from 2000 through 2009.Methods
Case identification
This is a retrospective study reviewing of medical records at
National Cheng Kung University Hospital, a tertiary referral
hospital in southern Taiwan, for all infants with either
BW < 1500 g or gestational age (GA) < 32 weeks admitted
between January 1, 2000, and December 31, 2009. We
excluded those infants who failed to survive longer than 28days for the first ROP screening, who did not live for 6
months postnatally to complete ROP screening, and who
had congenital diseases such as chromosomal anomaly. The
study protocol was approved by the institutional review
board of National Cheng Kung University Hospital.
Retinopathy assessment
ROP was staged using ICROP.1,5 The first ROP screening
examination for infants born before 27 weeks GA was
carried out at 31 to 33 weeks postmenstrual age and that
for infants born between 27 and 32 weeks GA was under-
taken at 4 weeks postnatal age. For this examination, both
pupils were dilated by instillingone drop of 0.5% tropica-
mide and 0.5% phenylephrine three times until full dilation
occurred. Indirect ophthalmoscopy was performed using
a lid speculum and scleral indentation.
The stage of ROP was not determined by just one single
examination. Instead, the eyes were reexamined on
a weekly or biweekly basis, depending on the fundus find-
ings of the screening examination. Eyes without ROP were
reexamined biweekly by retinal specialists (Drs Li, Hsu, and
Chang) until full vascularization of the retina was achieved.
Those with ROP were examined every week until regression
occurred or until ROP reached the threshold for laser or
cryotherapy treatment.7 The highest stage of ROP recorded
was assigned to each infant.
From 2000 until the end of 2007, eyes were treated if
they met the ICROP classification1,5 for threshold disease,
which is defined as stage 2 ROP with plus disease with 5
contiguous clock hours of disease or a total of 8 noncon-
tiguous clock hours in zone 1 or 2.22 After 2007, eyes were
treated if they had type 1 ROP according to the ETROP
criteria,7 in which type 1 ROP was defined as (1) any stage
with plus disease in zone I, or (2) stage 3 ROP without plus
disease in zone I, or (3) disease in zone II that was at stage 2
or 3 with plus disease. Eyes with threshold ROP or type 1
ROP were treated with indirect diode laser photocoagula-
tion or cryotherapy under general anesthesia.
Assessment of risk factors for ROP
In addition to BW and GA, we assessed the following for
association with ROP: in-hospital or out-of-hospital birth,
paternal age, maternal age, multiple gestations, parity,
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stay, respiratory distress syndrome (RDS), mechanical
ventilation, chronic lung disease (CLD), patent ductus
arteriosus (PDA), prenatal maternal usage of steroid,
postnatal surfactant use, postnatal indomethacin use,
sepsis, intraventricular hemorrhage, upper gastrointestinal
bleeding, blood transfusion, and necrotizing enterocolitis.
Refraction
Cycloplegic refraction of the eyes was performed using
a desktop computer autorefractometer (Topcon Corpora-
tion, Tokyo, Japan) after instilling onedrop of 0.5% tropi-
camide and 0.5% phenylephrine three times until the pupil
dilated. Infants who were too small for desktop computer
autorefractometry were assessed using retinoscopy.
Refractive error values were converted to the spherical
equivalent (SE). Myopia worse than -6.0 diopters (D) was
considered to be advanced myopia. Anisometropia, or two
eyes that have unequal power, greater than 1.5 D, was
considered to be significant anisometropia. Refractive
status was recorded at the age of the last ophthalmic visit.
Statistical analyses
Statistical analyses were performed using the statistical
package for social sciences software (SPSS 17.0 forTable 1 Characteristics of 503 premature infants with or withou
(univariate analysis).
Characteristic Infants with ROP,
n Z 190 (37.8%)
Sex (% male) 101 (53.2)
Birth weight (g), number (%)
<750 35 (18.4)
750e999 83 (43.7)
1000e1249 52 (27.4)
1250e1499 15 (7.9)
1500 5 (2.6)
Mean (1 SD) 940 (251)
Gestational age (weeks), number (%)
<26 52 (27.4)
26e28 99 (52.1)
29e31 28 (14.7)
32e38 11 (5.8)
Mean (1 SD ) 27.0 (2.4)
Out-of-hospital birth 33.5%
Other characteristics, mean  1 SD
Paternal age (years) 34.1  5.6
Maternal age (years) 31.5  5.0
Multiple gestation 2.3  1.4
Parity (number) 1.7  0.8
Apgar score, 1 minute 4.7  2.0
Apgar score, 5 minutes 6.9  1.8
Length of hospital stay (days) 66.2  39.8
ROP Z retinopathy of prematurity; SD Z standard deviation.Windows, SPSS Inc., Chicago, IL, USA) and Microsoft Excel
software (Microsoft Corporation, Redmond, WA, USA).
Descriptive statistics were expressed as mean  1 standard
deviation. The chi-square test was used to compare cate-
goric data related to clinical outcomes. Student t test and
analysis of variance were used to compare continuous data.
Univariate analyses were used to test for the potential risk
factors of ROP. If significant at p < 0.05, risk factors were
included in the stepwise multivariable logistic regression
analyses. The adjusted odds ratio and corresponding 95%
confidence interval for the incidence of ROP was calculated
for the risk factors in the model.
Results
Patient characteristics
Five hundred three infants (255 male and 248 female) met
the criteria for inclusion in this study. Their BWs ranged
from 455 to 1968 g (1157  313) and GA ranged from 21 to
38 weeks (29.1  2.7). ROP was identified in 190 infants
(37.8%), and 59 infants (11.7%) underwent laser photoco-
agulation therapy or cryotherapy.
Table 1 summarizes the characteristics of the 503 infants
with or without ROP on the screening examination. There
was a statistically significant difference in BW for infants
with and without ROP (mean BW for those witht retinopathy of prematurity on initial screening, 2000e2009
Infants without ROP,
n Z 313 (62.2%)
p
154 (49.2)
8 (2.6)
41 (13.1)
84 (26.8)
117 (37.4)
63 (20.1)
1288 (272) <0.001
4 (1.3)
64 (20.4)
173 (55.3)
72 (23.0)
30.1 (2.1) <0.001
26.3% 0.106
33.4  6.0 0.406
29.9  5.3 0.006
2.1  1.8 0.330
1.6  0.7 0.064
5.6  2.0 <0.001
7.8  1.7 <0.001
45.1  33.5 <0.001
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p < 0.001). Of the 503 infants, 435 had very low BW (VLBW)
(<1500 g), and 185 (42.5%) of the 435 had ROP. However, of
the 167 with extremely low BW (ELBW) (<1000 g), 118
(70.7%) had ROP, compared with only 49 (29.3%) of those
without ROP. As for the remaining 68 newborns weighing
>1500 g, only 5 (7.4%) screened positive for ROP and none
of them required treatment.
There was also a statistically significant difference in GA
between infants with and those without ROP (GA 27.0  2.4
weeks for those with ROP vs. 30.1  2.1 weeks for those
without ROP, p < 0.001). Additionally, ROP was more
prevalent among infants born to older mothers, those with
lower Apgar scores, and those with prolonged hospital stays
(Table 1).Correlation of stage of ROP with BW and GA
As shown in Table 2, the stage of ROP correlated inversely
with BW and GA. On average, infants with BWs < 900 g were
more likely to develop threshold ROP or even more
advanced stages that required treatment; however, there
were a number of newborns weighing <900 g with ROP who
did not reach the threshold level for treatment.Likewise,
the mean BW of infants undergoing treatment for ROP was
significantly lower than those with ROP not requiring
treatment and lower than those without ROP (819  214 vs.
995  248 vs. 1288  272 g, p < 0.001)(Table 3). Fig. 1
shows the proportions of infants with treated ROP,
untreated ROP, and no ROP, by BW. Among infants with
VLBW and ELBW, 13.6% and 29.3%, respectively, required
treatment for ROP.
A similar correlation was seen for GA, which was signifi-
cantly lower for infants with ROP who required treatment
compared with those with ROP not requiring treatment and
those without ROP (26.4  2.7 vs. 27.4  2.5 vs. 30.2  2.7
weeks, p < 0.001) (Table 3). Overall, among infants with
a GA < 32 weeks versus >32 weeks, ROP was diagnosed in
42.6% versus 13.3%, respectively. Fig. 2 shows the proportions
of infants with treated ROP, untreated ROP, and no ROP, by
GA. Among infants with GA< 26 weeks, 26e28 weeks, 29e31
weeks, and >32 weeks, treatment for ROP was required by
42.9%, 16.7%, 3.4%, and 1.2%, respectively. Only one infant in
the>32-week GA group (GAZ 33 weeks) required treatment
for ROP and this infant had a BW of 1120 g.Table 2 Maximum ROP stage on screening of 503 infants, by bi
Maximum ROP stage Number (%) Bir
me
None 313 (62.2) 128
Stage 1 61 (12.1) 103
Stage 2 36 (7.2) 960
Stage 3 subthreshold 34 (6.8) 969
Threshold (3þ) 47 (9.3) 817
Stage 4 11 (2.2) 841
Stage 5 1 (0.2) 660
Total patients 503 (100) 115
ROP Z retinopathy of prematurity; SD Z standard deviation.After the treatment (retinal photocoagulation or cryo-
therapy), ROP regressed in 83.1% (n Z 49) of the treated
infants. In the other 16.9% (n Z 10), ROP progressed to
either stage 4 or 5 and required further surgical
intervention.
Refractive status of infants with ROP
A total of 113 infants (55 male and 58 female) were brought
back to the hospital for refractive examination. The mean
age at this examination was 2.7  2.5 years (range, 0.2 to
9.7 years). Mean refractive error in these 113 infants was
close to emmetropia (0.02  3.23 D), although the ranges
were large (þ7.25 to 13.50 D).
Of these 113 infants, 25 (50 eyes) had undergone
treatment for ROP. Three of them progressed to stage 4
and the others regressed. As shown in Fig. 3, the 50 eyes
that were treated for ROP had SEs of 3.50  4.27 D; 38
(76.0%) of these 50 eyes were myopic. Mean SEs in eyes
with untreated ROP were 0.53  2.13 D,which were close
to emmetropia,and eyes without ROP had mean SEs of
1.57  1.53 D.
Advanced myopia (<6.0 D) was noted in only 10 of 113
infants (8.4%), but in 17 eyes of 50 treated eyes (34.0%)
(p < 0.001). Significant anisometropia (>1.5 D) was present
in 12 of 113 infants (10.6%) and was found in a higher
proportion of infants with treated ROP (n Z 7) compared
with untreated ROP (n Z 5) or no ROP (n Z 0) (28.0%,
11.1%, and 0% respectively), and the differences were
significant (pZ 0.004).
Risk factors for ROP
On univariate analysis, patient characteristics associated
with ROP were lower BW, younger GA, lower Apgar scores
at 1 minute and 5 minutes, and longer length of hospital
stay (Table 1). In addition, a significantly higher proportion
of infants with ROP versus those without ROP had RDS, CLD,
PDA, administration of surfactant or indomethacin, sepsis,
upper gastrointestinal bleeding, blood transfusion, or
necrotizing enterocolitis (Table 4).
However, the stepwise multivariate logistic regression
analysis showed that only low BW (adjusted odds ratio
0.996 [95% confidence interval 0.993e0.998]) was predic-
tive of the development of ROP.rth weight and gestational age.
th weight in grams,
an  1 SD (range)
Gestational age in weeks,
mean  1 SD (range)
8  272 (542e1968) 30  2.1 (23e36)
0  238 (455e1716) 28  2.4 (24e38)
 236 (472e1480) 27  2.3 (24e35)
 274 (560e1760) 26  2.3 (21e30)
 201 (460e1438) 26  1.8 (23e32)
 275 (600e1484) 26  2.9 (24e33)
24
7  313 (455e1968) 29.1  2.7 (21e38)
Table 3 Mean BW and GA in no ROP, untreated ROP, and treated ROP groups.
No ROP,
n Z 313 (62.2%)
Untreated ROP,
n Z 131 (26.0%)
Treated ROP,
n Z 59 (11.7%)
p
Mean BW  1 SD (g) 1288  272 995  248 819  214 <0.001
Mean GA  1 SD (weeks) 30.2  2.7 27.4  2.5 26.4  2.7 <0.001
BW Z birth weight; GA Z gestational age; ROP Z retinopathy of prematurity; SD Z standard deviation.
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In our study, higher incidence of ROP has a significant
association with lower BW, younger GA,lower Apgar scores
at 1 minute and 5 minutes, longer length of hospital stay,
RDS, CLD, PDA, administration of surfactant or indometh-
acin, and sepsis, upper gastrointestinal bleeding, blood
transfusion, or necrotizing enterocolitis on univariate
analysis. However, on multivariate analysis, higher risk of
ROP was predicted only by BW. Risk factors reported in the
literature vary, in many cases attributable to differences in
methodology, screening criteria, and indications for treat-
ment of ROP.
Regarding the relative predictive value of BW and GA,
although GA is highly correlated with BW, a number of
studies23,24 have previously reported that BW is a stronger
predictor of ROP than GA. When compared with full-term
infants, low BW infants are especially at increased risk of
visual impairment.25 Two explanations for these findings
have been given: (1) the high error rate when GA is esti-
mated based on prenatal ultrasound results and (2) the
possibility that premature infants with intrauterine growth
retardation might be at higher risk of developing ROP
because of their eventful clinical course, with conditions
such as RDS, sepsis, upper gastrointestinal bleeding,
necrotizing enterocolitis, and failure to thrive.
Regarding variations in screening criteria, the Royal
College of Pediatrics and Child Health (RCPCH)26 has rec-
ommended that infants with BW < 1501 g and/or GA < 32
weeks be screened for ROP, whereas the AmericanFigure 1 Rates of retinopathy of prematurity (ROPAcademy of Pediatrics has proposed screening for those
with BW < 1500 g and/or GA < 28 weeks.22 The screening
criteria we used in the study reported here are consistent
with those of the RCPCH. Even so, one infant who, at a GA
of 32 weeks and BW of 1760 g, did not meet RCPCH
guidelines for screening, developed stage 3 ROP in his right
eye. He was not born in a neonatal center, had an older
mother (37 years old), 1-minute Apgar score of 4, and
received supplemental oxygen for the first 3 days of life.
Although stage 3 ROP regressed spontaneously without
treatment in this case, it reminds us that some infants with
severe ROP might not meet current screening criteria.
Regarding what additional factors might predict the need
for screening, Fang et al.16 recommend that larger preterm
infants should be screened for ROP if they have lower 1-
minute Apgar scores, oxygen supplementation more than
40% or for longer than 5 days, or an unstable clinical course.
To these criteria, we would add, based on the study re-
ported here, older maternal age, lower 5-minute as well as
1-minute Apgar scores,and oxygen supplementation as
criteria for ROP screening.
Regarding the relationship of ROP to BW and GA, ROP
was diagnosed in 37.8% of 503 infants with GA < 32 weeks
or BW < 1500 g. Among VLBW infants (<1500 g), the inci-
dence of ROP was 42.5% and among ELBW infants (<1000 g)
the incidence was 70.7%. Our overall incidence and inci-
dence among VLBW infants are comparable to the 42.5%
incidence of ROP reported in Taiwan between 1988 and
199127and a 36.5% incidence reported for the period 1996 to
2000.13 Among older premature infants (GA < 37 weeks),) stratified by birth weight (BW) and treatment.
Figure 2 Rates of retinopathy of prematurity (ROP) stratified by gestational age (GA) and treatment.
450 M.-L. Li et al.Wu et al.15 reported an incidence of ROP of just 13%. In the
CRYO-ROP trial, the incidence of ROP was 65.8% among
infants with BW < 1250 g and 81.6% in ELBW infants.
Compared to this most widely cited CRYO-ROP study
conducted in the mid-1980s, our results show approxi-
mately 10% lower incidences of ROP for infantswith
BW < 1250 g (56.1%) and ELBW (70.7%). Results similar to
ours, however, were reported in a Taiwan study (36.5%
incidence in infants <1600 g and 59.5 % incidence in ELBW
infants).13
In studies conducted among western populations, inci-
dences of ROP ranged between 15.7% and 48.9%,28e31 with
a trend toward lower rates over time. This trend has been
attributed to improvements in care for premature infants,
such as surfactant prophylaxis to improve pulmonary
maturity, continuous pulse oximetry, antenatal maternal
steroids, and use oflower concentrations of oxygen.32e34
Without long-term longitudinal studies conducted among
the same population using the same criteria, it is difficult
for us to determine whether the incidence of ROP is
changing in Taiwan.Treated ROP
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Figure 3 Comparisons of refractive status among treated
retinopathy of prematurity (ROP), untreated ROP, and no ROP
groups. D Z diopter.As the numbers of infants with ELBW and VLBW who
survive increase,9,20,21,35,36 more infants are likely to
require screening for ROP. Moreover, as improvements in
care lead to survival of more ELBW infants without major
neurologic or cognitive deficits,37 detection and treatment
of ROP will be increasingly important to ensure optimal
quality of life for these patients. In the study we report
here, the incidence of treated ROP was 29.3% among ELBW
infants. Incidences of ROP meeting treatment criteria in
other recent domestic studies13e15 differ from ours
depending on study criteria. Yang et at.14 reported an
incidence of 13.5% for ROP requiring treatment between
1994 and 2003, whereas Liu et at.13 reported a lower inci-
dence of ROP requiring treatment (8.2%) in premature
infants weighing <1600 g. However, in a Beijing study,38 the
incidence of treated ROP was 28.6% and 28.7% in a study of
ELBW infants in the United States.24 Both findings are
comparable to our results. Nonetheless, a study among
Japanese infants found indications for treatment in up to
41%, which might be attributed to an 86.1% incidence of
ROP for ELBW infants.39 However, only 17.0% of ELBW
infants in a Brazil study were treated.31
Retinal neovascularization leads to retinal traction,
retinal hemorrhage, and retinal detachment, finally
affecting vision. In the past decade, the recommended
treatment for type 1 and threshold ROP was peripheral
ablation, and laser therapy was the preferred method of
treatment rather than cryotherapy. However, the use of
anti-vascular endothelial growth factor agents, primarily
intravitreal bevacizumab, is currently an emerging treat-
ment for type 1 and threshold ROP s.40 Off-label use of
intravitreal bevacizumab therapy as monotherapy and in
combination with conventional laser therapy or vitrec-
tomy or both18 are current treatment options for type 1
and threshold ROP and the results seem promising. In our
study, regression of retinal neovascularization was noted
in 83.1% of the infants whose disease was treated. Our
result is similar to that in the CRYO-ROP study,6 in which
74% of the eyes had a favorable outcome at 1 year, and
almost the same as the 84% with a favorable outcome in
the conventional treatment arm of the ETROP trial7 at 9
months. Our result is comparable as well to results in
other published studies.6,7,40,41 Although laser therapy or
Table 4 Risk factors in newborns with or without retinopathy of prematurity (ROP) (univariate analysis).
Risk factors Newborns without
ROP, n Z 313
Newborns with
ROP, n Z 190
p
Respiratory distress syndrome* 67.7% 86.2% <0.001
Mechanical ventilation 86.9% 84.2% 0.57
Chronic lung disease* 27.0% 64.8% <0.001
Patent ductus arteriosus* 39.6% 58.5% 0.001
Steroid exposure prenatally 72.8% 78.5% 0.224
Surfactant usage* 26.9% 53.1% <0.001
Indomethacin usage* 42.9% 71.7% <0.001
Sepsis* 41.6% 61.2% <0.001
Intraventricular hemorrhage 19.2% 26.3% 0.113
Upper gastrointestinal bleeding* 16.0% 34.6% <0.001
Blood transfusion* 37.6% 58.1% <0.001
Necrotizing enterocolitis* 15.7% 26.1% 0.006
*Statistically significant at the level of p < 0.05.
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4 ROP in most patients, these treatments actually destroy
the peripheral retina and may lead to visual field defect
and refractive changes. Therefore, the new treatment
option, intravitreal bevacizumab therapy, may prevent
visual field defect, especially in zone I ROP patients,40 and
decrease the possibility of progression to stage 4 or 5 after
peripheral ablation, whereby functional visual outcomes
are still not satisfying, even after vitrectomy or scleral
buckling.42,43
Major concerns for premature infants, particularly those
with ROP, are development of the eye, refractive status,
and visual outcome. In the current study with an average
follow-up of 2.7 years,the mean refractive errors of eyes
without ROP, with untreated ROP, treated ROP were þ1.5
D, þ0.5 D, and -3.5 D, respectively.Approximately 75% of
treated eyes in our study had myopia and approximately
25% hadadvanced myopia (<-6.0 D).Yang et al19 reported
similar results in a recent domestic study: 77% of laser-
treated eyes were myopic and 16.7% had worse than -6.0
D of myopia at an average patient age of 7 years.
Rates of myopia may vary among studies because the
incidence of myopia increases with increasing prematurity
and severity of ROP.44e46 Myopia in infants with ROP is
believed to be partly due to the disease process of ROP and
partly a result of therapy for ROP. Factors accounting for
this relationship include anomalies of corneal diameter and
curvature, shorter anterior chamber, axial length, thicker
lens, and laser effects on the sclera.6,44,47,48 A combination
of various optical components results in complicated
refractive outcomes. Another study found that lower BW
and greater severity of ROP strongly predicted myopia and
high myopia.25,47,49 Of note, Tasman50 reported that
patients withROP and a high degree of myopia had a higher
rate of retinal detachment in later life. This indication that
ROP has lifelong consequences means that long-term
follow-up is crucial for patients with treated ROP.
The risk factors for ROP we identified in univariate
analysis (RDS, CLD, PDA, surfactant usage, indomethacin
usage, sepsis, upper gastrointestinal bleeding, blood
transfusion, and necrotizing enterocolitis) are in line with
findings in other studies that ROP is associated withcomplex medical conditions that require prolonged treat-
ment with oxygen.29,51,52 However, lower BW was the most
important predictor of ROP.
Our study has three major limitations. The first is its
design, as a retrospective study with relatively small
sample size compared with some other studies in the
literature.2,4,6,7,24,29,45,49 Ideally, a large, carefully
designed population-based cohort study should be con-
ducted of ROP throughout Taiwan. Second, the incidence of
ROP in our study simply represented the clinical observa-
tions of premature infants at a single tertiary medical
center and could not reflect the exact incidence of ROP in
the area of southern Taiwan. Third, the refractive status in
our study was examined at different ages among the study
participants. This lack of a standardized age for final
evaluation made it difficult to generalize and compare
results among the study groups. An ideal study would
measure refractive outcomes, optical components, and
functional outcomes, such as visual acuity, at standardized
ages over the long term, to assess the risk for amblyopia
and other sequelae of ROP at various times/ages after
treatment.
In conclusion, our study confirmed the findings in
previous studies that low BW significantly increases the risk
for ROP. ELBW infants are at even higher risk of ROP and of
more advanced ROP requiring immediate treatment
compared with those with VLBW. Myopia and subsequent
amblyopia and other ocular sequelae of ROP may cause
lifelong problems.Financial support
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